profit from every $100 of sales.
$0$100
Prenetics Global
$16.51-1.26% today
+22.6% in 1 year
1-year low $11.791-year high $26.25
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Prenetics Global sold, what it kept, and what it did with the cash.
Sales went from $13.2 million in 2022 to $92.4 million in 2025, with -$37.7 million of profit last year.
SalesProfit
Prenetics Global vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Prenetics Global | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Prenetics Global's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13 | 6 | 16 | 92 | |
| 4 | 1 | 9 | 49 | |
| -66 | -42 | -38 | -38 | |
| -218 | -35 | -40 | -32 | |
| -190 | -63 | -46 | -38 | |
| -37.50 | -5.58 | -3.71 | – | |
| 27.5% | 19.1% | 58.2% | 52.8% | |
| -500.7% | -690.0% | -240.2% | -41.3% | |
| -1,446.8% | -1,019.1% | -290.6% | -40.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 312 | 254 | 214 | 206 |
| Cash | 147 | 46 | 52 | 32 |
| Total debt | 7 | 2 | 6 | 2 |
| Total liabilities | 69 | 44 | 42 | 50 |
| 237 | 206 | 170 | 156 | |
| 5 | 11 | 12 | – | |
| -73.1% | -16.2% | -20.6% | -18.0% | |
| -80.3% | -30.4% | -27.2% | -24.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 15 | -14 | -29 | -22 | |
| 6 | 1 | 1 | 55 | |
| 8 | -15 | -30 | -76 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 0 | |
| 121 | 11 | 12 | 8 |
Valuation
- –
- –
- –
- 3.0×
- 3.5×
- –
- –
- -23.7%
- -11.7%
- 0.0%
Profitability
- 52.8%
- -41.3%
- -40.8%
- -48.8%
- -25.5%
- -69.5%
- -46.7%
- -40.5%
- -25.6%
- 4.0%
Growth
- +91.5%
- –
- +26.5%
- –
- +39.6%
Financial health
- -0.9×
- 0.00
- 0.3%
- -232.3×
- 5.15
- 4.60
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 952
Bottom 7%of 884
Top 7%of 886
Bottom 3%of 987
What analysts expect
- Average price target
- $36.00
- Range
- $36.00 – $36.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.14 | -0.49 | −131.6% |
| Feb 18, 2026 | -0.27 | -0.49 | +44.9% |
| Nov 10, 2025 | -0.41 | -0.55 | +25.5% |
| Sep 12, 2025 | -0.82 | -0.71 | −15.5% |
| Jun 12, 2025 | -0.80 | -0.77 | −3.9% |
| Mar 5, 2025 | -1.29 | -0.72 | −78.6% |
| Nov 27, 2024 | -0.88 | -0.93 | +5.4% |
| Sep 27, 2024 | -0.15 | -0.93 | +83.9% |
News
OptimumBank outlines $48M-$50M annual pretax pre-provision run rate as it targets 2027 HUD licenseSeeking Alpha · Nov 13, 2026Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; Nvidia to Advance, Microsoft to DeclineYahoo Finance · Nov 13, 2026Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Nvidia Stock RecoversYahoo Finance · Nov 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
40No pass
Philip Fisher
43No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
31No pass
Questions about Prenetics Global
Is Prenetics Global a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Prenetics Global AI analysis
What does Prenetics Global do?
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. It is in Medical - Diagnostics & Research.
Does Prenetics Global pay a dividend?
No. Prenetics Global does not pay a dividend at the moment.
Is Prenetics Global stock halal?
Yes. Prenetics Global passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
How has Prenetics Global stock done over the past year?
Up 22.6% over the past twelve months, to $16.51. It traded between $11.79 and $26.25 and is 37.1% below its high.
Who are Prenetics Global's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Prenetics Global's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.